Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice
CP and lenvatinib provided effective outcomes in metastatic thymic carcinoma, aligning with previous findings. S-1 and sunitinib also show clinical activity but with variable responses in liver metastases. These results highlight the importance of tailored treatment strategies, particularly for patients with liver involvement.
Authors
- M. Torasawa
- Yusuke Okuma (ORCID: https://orcid.org/0000-0001-5743-0149)
- Yuki Shinno (ORCID: https://orcid.org/0000-0002-1813-4184)
- Noboru Yamamoto (ORCID: https://orcid.org/0000-0002-0787-2851)
- Yasushi Goto (ORCID: https://orcid.org/0000-0002-7437-5054)
- Motoko Arakaki
- Yukiko Shimoda Igawa
- Hidehito Horinouchi (ORCID: https://orcid.org/0000-0001-9090-801X)
- Tsutomu Yoshida (ORCID: https://orcid.org/0000-0002-6963-5827)
- A.T. Tateishi
- Yuichiro Ohe (ORCID: https://orcid.org/0000-0002-6137-073X)
Institutions
- National Cancer Center Hospital East (JP)
- Tokyo National Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.21873/anticanres.17376
- Citations
- 2
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.74